Opus Point Partners Management LLC held its stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 112,300 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. Pfizer accounts for approximately 2.9% of Opus Point Partners Management LLC’s holdings, making the stock its 7th largest position. Opus Point Partners Management LLC’s holdings in Pfizer were worth $3,648,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in PFE. First Hawaiian Bank increased its position in shares of Pfizer by 0.3% in the third quarter. First Hawaiian Bank now owns 8,585 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 24 shares during the period. D Orazio & Associates Inc. increased its position in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares during the period. Peregrine Asset Advisers Inc. increased its position in shares of Pfizer by 0.5% in the fourth quarter. Peregrine Asset Advisers Inc. now owns 7,287 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 33 shares during the period. Alpha Windward LLC increased its position in shares of Pfizer by 0.5% in the third quarter. Alpha Windward LLC now owns 8,315 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 40 shares during the period. Finally, High Point Bank & Trust Co. increased its position in shares of Pfizer by 0.5% in the third quarter. High Point Bank & Trust Co. now owns 33,688 shares of the biopharmaceutical company’s stock valued at $1,141,000 after buying an additional 157 shares during the period. Institutional investors own 69.53% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded up 0.357% on Friday, hitting $32.335. 6,597,268 shares of the stock were exchanged. Pfizer Inc. has a 12 month low of $29.83 and a 12 month high of $37.39. The company has a 50-day moving average of $33.63 and a 200-day moving average of $32.89. The stock has a market cap of $192.97 billion, a price-to-earnings ratio of 27.218 and a beta of 0.94. Pfizer also saw unusually large options trading activity on Tuesday. Traders bought 1,119 put options on the stock. This is an increase of approximately 137% compared to the average volume of 473 put options.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.02. Pfizer had a net margin of 13.50% and a return on equity of 23.18%. The company had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $13.09 billion. During the same quarter last year, the firm posted $0.67 EPS. The firm’s revenue was down 1.7% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post $2.55 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 1st. Shareholders of record on Friday, May 12th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.97%. The ex-dividend date of this dividend is Wednesday, May 10th. Pfizer’s payout ratio is 110.35%.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2017/05/19/opus-point-partners-management-llc-continues-to-hold-stake-in-pfizer-inc-pfe-updated.html.
Several brokerages recently weighed in on PFE. Barclays PLC set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Thursday, March 16th. Vetr cut shares of Pfizer from a “hold” rating to a “sell” rating and set a $33.45 price objective on the stock. in a research note on Thursday, March 2nd. Societe Generale reaffirmed a “neutral” rating and set a $36.00 price target on shares of Pfizer in a research report on Thursday, March 23rd. BMO Capital Markets reaffirmed a “hold” rating and set a $33.00 price target on shares of Pfizer in a research report on Tuesday, March 21st. Finally, Sanford C. Bernstein reaffirmed a “buy” rating and set a $35.00 price target on shares of Pfizer in a research report on Friday, March 24th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and a consensus price target of $37.54.
In other Pfizer news, insider Charles H. Hill sold 36,000 shares of the stock in a transaction dated Thursday, March 9th. The shares were sold at an average price of $34.07, for a total transaction of $1,226,520.00. Following the transaction, the insider now directly owns 57,329 shares in the company, valued at approximately $1,953,199.03. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mikael Dolsten sold 30,970 shares of the firm’s stock in a transaction dated Thursday, March 2nd. The shares were sold at an average price of $34.51, for a total transaction of $1,068,774.70. Following the completion of the sale, the insider now owns 64,719 shares in the company, valued at $2,233,452.69. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,470 shares of company stock worth $2,449,150. 0.07% of the stock is owned by company insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.